Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 2Melanoma 2Endometrial Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Rectal Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Hodgkin Disease 1Hepatoblastoma 1Head and Neck Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Temozolomide 8Irinotecan 7Vincristine 6Nivolumab 2temsirolimus 1talazoparib 1surufatinib 1sonidegib 1silmitasertib 1regorafenib 1prexasertib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1irinotecan sucrosofate 1holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1ganitumab 1eribulin 1efineptakin alfa 1dostarlimab 1dinutuximab 1copanlisib 1bempegaldesleukin 1atezolizumab 1adavosertib 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdomyosarcoma × dostarlimab × Clear all
NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡